

*At 1
Conclude
2*

--23. The process of claim 22, wherein said strong promoter is a CMV promoter.--

Abstract of the disclosure

An agent for the treatment of septicemia containing as the active component protein binding liposaccharide (LBP), its variants, mutants, or hybrid proteins.

Remarks


Claims 12-23 are in the application.


It is respectfully submitted that no new matter was added to the enclosed substitute disclosure. Enclosed herewith is a redline copy to show the changes that went into the substitute disclosure, together with a change listing.

Favorable action is urged.

GABRIEL P. KATONA L.L.P.
708 Third Avenue, 14th Floor
New York 10017
(212)370-4000

Respectfully submitted


Gabriel P. Katona
attorney of record

I hereby certify that this correspondence is deposited with the U.S. Postal Service, addressed as above, on January 16, 2001.

Cynthia A. Pilato